首页> 外国专利> Spinosyn formulations for treatment of demodex-induced ocular and facial conditions

Spinosyn formulations for treatment of demodex-induced ocular and facial conditions

机译：Spinosyn制剂用于治疗蠕形螨病诱发的眼部和面部疾病

页面导航

摘要
著录项
相似文献

摘要

The present invention concerns materials and methods for treating an ocular Demodex mite infestation of an eye of a human or animal subject, or for treating a condition of the eye or skin associated with ocular Demodex mite infestation, the method comprising topically administering a composition comprising one or more spinosyn compounds to the ocular surface (conjunctiva and/or cornea) or other anatomical structure of the eye, or to an area adjacent the eye.

机译：本发明涉及用于治疗人或动物的眼睛的眼部 Demodex 螨虫侵袭，或用于治疗与眼部 Demodex 相关的眼睛或皮肤疾病的材料和方法。螨侵害，该方法包括向眼睛的眼表面（结膜和/或角膜）或其他解剖结构或与眼睛相邻的区域局部施用包含一种或多种多杀菌素化合物的组合物。 展开▼

著录项

公开/公告号US10730901B2

专利类型

公开/公告日2020-08-04

原文格式PDF

申请/专利权人 APERTA BIOSCIENCES LLC;
展开▼

申请/专利号US201916523984

发明设计人 CARLOS SANTOS;IUAN-BOR CHEN;JOSUE MORAN;
展开▼

申请日2019-07-26

分类号C07H17/08;A61K9;A61K9/107;A61K47/10;A61K47/44;A61K47/14;A61K47/32;A61K8/37;A61K8/368;A61K8/92;A61K8/81;A61K8/34;A61K47/12;A61K45/06;

国家 US

入库时间 2022-08-21 11:27:33

相似文献

专利

外文文献

中文文献

1. 用于治疗蠕形螨引起的眼部和面部疾病的多杀菌素制剂 [P] . 中国专利： CN112770742A . 2021-05-07

2. 一种用于治疗眼部疾病缓解眼部不适的中药制剂及其制备方法 [P] . 中国专利： CN107669807A . 2018-02-09

3. SPINOSYN FORMULATIONS FOR TREATMENT OF DEMODEX-INDUCED OCULAR AND FACIAL CONDITIONS [P] . US2021147464A1 . 2021-05-20

机译：用于治疗Demodex诱导的眼部和面部条件的Spinosyn制剂

4. SPINOSYN FORMULATIONS FOR TREATMENT OF DEMODEX-INDUCED OCULAR AND FACIAL CONDITIONS [P] . EP3829569A1 . 2021-06-09

机译：用于治疗Demodex诱导的眼部和面部条件的Spinosyn制剂

5. SPINOSYN FORMULATIONS FOR TREATMENT OF DEMODEX-INDUCED OCULAR AND FACIAL CONDITIONS [P] . 美国专利： US2020031859A1 . 2020-01-30

机译：纺锤体配方治疗脱模引起的眼部和面部疾病

1. Facial nucleus up-regulation of brain-derived neurotrophic factor mRNA following electroacupuncture treatment in a rabbit model of facial nerve injury [J] . Hong Gao, Bangyu Ju, Guohua Jiang 中国神经再生研究（英文版） . 2008,第011期

2. A stepwise optimization strategy to formulate in situ gelling formulations comprising fluconazole-hydroxypropyl-beta-cyclodextrin complex loaded niosomal vesicles and Eudragit nanoparticles for enhanced antifungal activity and prolonged ocular delivery [J] . Heba Elmotasem, Ghada E.A.Awad 亚洲药物制剂科学(英文) . 2020,第005期

3. Novel approaches for posterior segment ocular drug delivery with folate-modified liposomal formulation [J] . Toshiki Hayashi, Risako Onodera, Kohei Tahara, 亚洲药物制剂科学(英文) . 2016,第001期

4. New micelle myricetin formulation for ocular delivery: improved stability, solubility, and ocular anti-inflammatory treatment [J] . Fengyuan Sun, Zhou Zheng, Jie Lan, Drug delivery. . 2019,第1期

5. New nanomicelle curcumin formulation for ocular delivery: improved stability, solubility, and ocular anti-inflammatory treatment [J] . Li Mengshuang, Xin Meng, Guo Chuanlong, Drug development and industrial pharmacy . 2017,第7a12期

6. Self-induced facial excoriations and ocular trauma: A treatment dilemma [J] . MahoneyN.R., AndersonR.L., McCannJ.D., British journal of ophthalmology . 2012,第3期

7. ANALYTICAL FORMULATION AND DAMPING ANALYSIS OF BEAMS WITH ENHANCED ACTIVE CONSTRAINED LAYER TREATMENTS UNDER VARIOUS BOUNDARY CONDITIONS [C] . J. X. Gao, W. H. Liao American Society of Mechanical Engineers(ASME) International Design Engineering Technical Conferences and Computers and Information in Engineering Conference 2005(DETC2005) vol.1: Biennial Conference on Mechanical Vibration and Noise pt.C; 20050924-28; L . 2005

8. Development of Random Triblock Copolymer Based Nanoparticulate Formulation for Sustained Release of Macromolecules/Biologics in Treatment of Posterior Segment Ocular Diseases [D] . Joseph Ngatuni, Mary. 2018

9. New micelle myricetin formulation for ocular delivery: improved stability solubility and ocular anti-inflammatory treatment [O] . Fengyuan Sun, Zhou Zheng, Jie Lan, 2019

10. Ex-Vivo Trans-Corneal and Trans-Scleral Diffusion Studies with Ocular Formulations of Glutathione as an Antioxidant Treatment for Ocular Diseases [O] . María Sebastián-Morelló, Adrián M. Alambiaga-Caravaca, María Aracely Calatayud-Pascual, 2020

11. Primary Ocular Irritation of Two CHF 1 Formulation Components: Dow Corning 200 and Isopropanol [R] . Kellner, T. P., Hanes, M. A., Fruin, J. T. 1982

1. RACIAL DIFFERENCES OF OPTIC DISC TOPOGRAPHY IN OCULAR HYPERTENSIVE EYES: RESULTS FROM THE CONFOCAL SCANNING LASER OPHTHALMOSCOPY ANCILLARY STUDY TO THE OCULAR HYPERTENSION TREATMENT STUDY [J] . . 国际眼科杂志 . 2003,第001期

2. Effects of Curing Conditions and Formulations on Residual Monomer Contents and Temperature Increase of a Model UV Gel Nail Formulation [J] . Kentaro Taki ,Tomomi Nakamura . 化妆品、皮肤病及应用期刊（英文） . 2011,第4期

3. 溴芬酸钠滴眼液用于眼部疾病的卫生技术评估 [C] . ZHOU Pengxiang ,周鹏翔 ,MEN Peng . 2017年中国药学大会暨第十七届中国药师周 . 2017

4. 用于口腔黏膜疾病治疗的盐酸苄达明壳聚糖缓释型粉雾制剂的研究 [A] . 姜旺展 . 2013